细胞和基因治疗市场规模、份额和成长分析（按治疗类型、治疗层级、递送方法、最终用户和地区）：产业预测（2024-2031）

2022年全球细胞和基因治疗市场规模预计为177亿美元，从2023年的209.7亿美元扩大到2031年的815.5亿美元，预计在预测期内（2024-2031年）增长 2018 年复合年增长率。为18.50%）。

由于基因工程的进步和细胞研究投资的增加，预计未来几年细胞和基因治疗市场将显着成长。创新细胞和基因疗法在多种疾病中的广泛应用正在为产业相关人员创造新的机会。对加强患者照护的关注，加上对先进治疗方案的需求不断增加以及慢性病的流行，是推动市场扩张的关键因素。此外，个人化医疗的趋势和突破性治疗方法的监管核准率不断提高，进一步为该领域的新业务前景铺平了道路。然而，与先进治疗相关的挑战，例如高成本、有限的报销选择以及获得新疗法的机会有限，也可能阻碍创新解决方案的广泛采用。解决这些限制对于充分发挥细胞和基因治疗市场的潜力并将其定位为未来医学进步的关键领域至关重要。总体而言，技术创新和不断变化的患者需求相结合，表明细胞和基因治疗市场前景光明，使其成为医疗产业投资和发展的有吸引力的领域。

目录

介绍

• 分析目的
• 定义
• 市场范围

分析方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况及展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价值链分析
• 市场生态系统
• 案例研究分析
• 监管环境
• 主要投资分析
• 关键成功因素
• 竞争程度
• 市场魅力指数（2023）

细胞和基因治疗市场：按治疗类型

• 市场概况
• 细胞疗法
  • 干细胞
  • T细胞
  • 树突状细胞
  • 自然杀手细胞
  • 癌细胞
• 基因治疗
  • 基因静默
  • 细胞置换
  • 基因增强
  • 其他治疗方法

细胞/基因治疗市场：依治疗层级

• 市场概况
• 心血管疾病
• 癌症
• 遗传疾病
• 罕见疾病
• 肿瘤学
• 血液学
• 眼科
• 感染疾病
• 神经系统疾病
• 其他的

细胞和基因治疗市场：按输送方式

• 市场概况
• 体内
• 离体

细胞/基因治疗市场：依最终用户分类

• 市场概况
• 医院
• 癌症护理中心
• 其他的

细胞和基因疗法市场：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲 (MEA)
  • 波湾合作理事会(GCC) 国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Alnylam 製药公司（美国）
• 安进公司（美国）
• 百健公司（美国）
• CORESTEM Inc.（美国）
• Helixsmith Co. Ltd.（韩国）
• JCR 製药有限公司（日本）
• Kolon TissueGene Inc.（韩国）
• 诺华公司（瑞士）
• 辉瑞公司（美国）
• 吉利德科学公司（美国）
• Sangamo Therapeutics, Inc.（美国）
• 蓝鸟生物公司（美国）
• Zymeworks Inc.（加拿大）
• CRISPR Therapeutics AG（瑞士）
• Celyad Oncology SA（比利时）
• Atara Biotherapeutics, Inc.（美国）
• Athenex, Inc.（美国）
• 百时美施贵宝（美国）
• 协和麒麟（日本）
• 赛诺菲（法国）

Global Cell and Gene Therapy Market size was valued at USD 17.7 billion in 2022 and is poised to grow from USD 20.97 billion in 2023 to USD 81.55 billion by 2031, growing at a CAGR of 18.50% during the forecast period (2024-2031).

The cell and gene therapy market is set to experience significant growth in the coming years, driven by advancements in genetic engineering and increased investments in cellular research. The expanding application of innovative cell and gene therapies for a range of diseases presents new opportunities for industry players. A heightened focus on enhancing patient care, coupled with the rising demand for advanced treatment options and the growing prevalence of chronic diseases, are pivotal factors propelling market expansion. Additionally, the trend towards personalized medicine and the increasing rate of regulatory approvals for groundbreaking therapies further pave the way for new business prospects within this sector. However, the market does face challenges, namely the high costs associated with advanced therapies, limited reimbursement options, and restricted access to novel treatments, which may hinder broader adoption of these innovative solutions. Addressing these constraints will be essential for realizing the full potential of the cell and gene therapy market, positioning it as a key area for future healthcare advancements. Overall, the combination of technological innovation and evolving patient needs suggests a promising trajectory for the cell and gene therapy landscape, making it an appealing area for investment and development in the healthcare industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell And Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell And Gene Therapy Market Segmental Analysis

Global Cell and Gene Therapy Market is segmented by Therapy Type, Therapeutic class, Delivery Method, End-Users, and region. Based on Therapy Type, the market is segmented into Cell Therapy, Stem Cells (T Cells, Dendritic Cells, NK Cells, Tumor Cells), Gene Therapy (Gene Silencing, Cell Replacement, Gene Augmentation, Other Therapies). Based on Therapeutic class, the market is segmented into Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, and Others. Based on Delivery Method, the market is segmented into In Vivo, and Ex Vivo. Based on End-Users, the market is segmented into Hospitals, Cancer Care Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cell And Gene Therapy Market

Advancements in gene technologies are a significant market driver for the Global Cell and Gene Therapy market. These innovations, including CRISPR, recombinant DNA technology, and next-generation sequencing, have enhanced the precision and efficacy of gene editing and modification, paving the way for targeted therapies. With the increasing prevalence of genetic disorders, cancer, and rare diseases, these advanced technologies facilitate the development of more personalized and effective treatment options. Furthermore, ongoing research and investment in biopharmaceuticals are accelerating the translation of these technologies from the lab to clinical applications, propelling market growth and attracting both public and private funding.

Restraints in the Global Cell And Gene Therapy Market

One of the significant market restraints for the global cell and gene therapy market is the prohibitively high costs associated with these treatments. The complex and specialized nature of developing gene and cell therapies often results in substantial research and development expenditures, which are subsequently passed on to patients. This financial barrier limits access for a considerable segment of the population, potentially leading to disparities in treatment availability. Additionally, the high price tag poses challenges for healthcare providers and payers in terms of reimbursement and health insurance coverage, ultimately hindering market growth and patient adoption of these innovative therapies.

Market Trends of the Global Cell And Gene Therapy Market

The Global Cell and Gene Therapy market is witnessing a notable trend towards the increasing demand for combination therapies, which integrate the advantages of both gene and cell therapies. This trend is driven by a growing recognition of the high efficacy these integrated approaches offer in treating complex and multifaceted medical conditions. As healthcare professionals and patients alike seek more effective treatment options, cell and gene therapy companies are urged to innovate and develop novel combination therapies. This focus aims to enhance patient outcomes across a variety of disease indications, thereby positioning companies favorably within a rapidly evolving biopharmaceutical landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Top Investment Analysis
• Key Success Factor
• Degree of Competition
• Market Attractiveness Index, 2023

Cell and Gene Therapy Market by Therapy Type

• Market Overview
• Cell Therapy
  • Stem Cells
  • T Cells
  • Dendritic Cells
  • NK Cells
  • Tumor Cells
• Gene Therapy
  • Gene Silencing
  • Cell Replacement
  • Gene Augmentation
  • Other Therapies

Cell and Gene Therapy Market by Therapeutic class

• Market Overview
• Cardiovascular Disease
• Cancer
• Genetic Disorder
• Rare Diseases
• Oncology
• Hematology
• Ophthalmology
• Infectious Disease
• Neurological Disorders
• Others

Cell and Gene Therapy Market by Delivery Method

• Market Overview
• In Vivo
• Ex Vivo

Cell and Gene Therapy Market by End-Users

• Market Overview
• Hospitals
• Cancer Care Centers
• Others

Cell and Gene Therapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Alnylam Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CORESTEM Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helixmith Co. Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kolon TissueGene Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celyad Oncology SA (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atara Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athenex, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments